A RANDOMISED, DOUBLE-BLIND, PLACEBO CONTROLLED, REPEATED DOSE, THREE-WAY CROSSOVER STUDY TO EVALUATE THE PHARMACODYNAMICS, PHARMACOKINETICS AND SAFETY OF TWO DOSES OF CHF 6001 DPI IN SUBJECTS WITH MODERATE, SEVERE COPD.
Phase of Trial: Phase II
Latest Information Update: 08 Feb 2018
At a glance
- Drugs CHF 6001 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors Chiesi Farmaceutici SpA
- 17 Jan 2018 Status changed from recruiting to completed.
- 08 Dec 2016 New trial record